| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 53 | 2024 | 306 | 10.170 |
Why?
|
| Shock, Septic | 39 | 2024 | 102 | 7.870 |
Why?
|
| Acute Kidney Injury | 22 | 2023 | 295 | 3.960 |
Why?
|
| Child | 130 | 2024 | 6927 | 3.580 |
Why?
|
| Intensive Care Units, Pediatric | 34 | 2023 | 99 | 3.260 |
Why?
|
| Systemic Inflammatory Response Syndrome | 15 | 2023 | 49 | 2.400 |
Why?
|
| Multiple Organ Failure | 14 | 2024 | 53 | 2.320 |
Why?
|
| Child, Preschool | 70 | 2022 | 3612 | 2.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2023 | 878 | 2.190 |
Why?
|
| Infant | 58 | 2023 | 3046 | 1.930 |
Why?
|
| Critical Illness | 15 | 2023 | 294 | 1.830 |
Why?
|
| Hospital Mortality | 17 | 2022 | 349 | 1.600 |
Why?
|
| Adolescent | 62 | 2023 | 8981 | 1.440 |
Why?
|
| Hypotension | 2 | 2020 | 70 | 1.350 |
Why?
|
| Critical Care | 13 | 2022 | 370 | 1.340 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 746 | 1.280 |
Why?
|
| Retrospective Studies | 49 | 2023 | 8489 | 1.250 |
Why?
|
| Biomarkers | 27 | 2023 | 1718 | 1.230 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 89 | 1.230 |
Why?
|
| Humans | 147 | 2024 | 86643 | 1.210 |
Why?
|
| Kidney Diseases | 4 | 2023 | 418 | 1.070 |
Why?
|
| Vancomycin | 4 | 2022 | 72 | 1.060 |
Why?
|
| Respiratory Insufficiency | 8 | 2022 | 150 | 1.050 |
Why?
|
| Cytokines | 7 | 2022 | 776 | 0.950 |
Why?
|
| Intensive Care Units | 8 | 2023 | 373 | 0.950 |
Why?
|
| Severity of Illness Index | 21 | 2023 | 1801 | 0.910 |
Why?
|
| Heart Arrest | 4 | 2019 | 265 | 0.900 |
Why?
|
| Hospitals, Pediatric | 13 | 2022 | 106 | 0.880 |
Why?
|
| Male | 79 | 2023 | 40965 | 0.870 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 375 | 0.870 |
Why?
|
| Bacterial Infections | 3 | 2020 | 182 | 0.860 |
Why?
|
| Intubation, Intratracheal | 6 | 2023 | 144 | 0.850 |
Why?
|
| Shock | 3 | 2021 | 42 | 0.810 |
Why?
|
| Female | 76 | 2023 | 44532 | 0.810 |
Why?
|
| Prospective Studies | 29 | 2024 | 4213 | 0.760 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2023 | 139 | 0.710 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 140 | 0.700 |
Why?
|
| Risk Factors | 20 | 2023 | 5417 | 0.690 |
Why?
|
| Databases as Topic | 1 | 2019 | 92 | 0.670 |
Why?
|
| Infant, Newborn | 19 | 2022 | 2379 | 0.670 |
Why?
|
| Vaccination | 1 | 2020 | 254 | 0.650 |
Why?
|
| Research Design | 3 | 2020 | 594 | 0.620 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 157 | 0.600 |
Why?
|
| Heart Diseases | 1 | 2019 | 290 | 0.580 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2016 | 6 | 0.580 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2023 | 14 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 582 | 0.560 |
Why?
|
| Leukemia | 1 | 2018 | 320 | 0.550 |
Why?
|
| High-Frequency Ventilation | 2 | 2013 | 9 | 0.540 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 158 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 238 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 372 | 0.530 |
Why?
|
| Respiratory Tract Infections | 3 | 2023 | 105 | 0.520 |
Why?
|
| Quality of Life | 3 | 2024 | 1585 | 0.520 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2023 | 66 | 0.510 |
Why?
|
| Respiration, Artificial | 9 | 2024 | 334 | 0.510 |
Why?
|
| Organ Dysfunction Scores | 4 | 2022 | 27 | 0.500 |
Why?
|
| Prognosis | 17 | 2023 | 3679 | 0.500 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1621 | 0.470 |
Why?
|
| Communication | 1 | 2016 | 441 | 0.440 |
Why?
|
| Immunotherapy | 4 | 2021 | 629 | 0.440 |
Why?
|
| Proprotein Convertase 9 | 2 | 2023 | 20 | 0.430 |
Why?
|
| Noninvasive Ventilation | 2 | 2022 | 24 | 0.420 |
Why?
|
| Emergencies | 1 | 2011 | 113 | 0.400 |
Why?
|
| Length of Stay | 9 | 2021 | 702 | 0.390 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 316 | 0.390 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 151 | 0.390 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 301 | 0.390 |
Why?
|
| Brain Diseases | 2 | 2022 | 180 | 0.390 |
Why?
|
| Logistic Models | 10 | 2021 | 1186 | 0.390 |
Why?
|
| Blood Transfusion | 2 | 2022 | 157 | 0.390 |
Why?
|
| United States | 21 | 2023 | 6672 | 0.390 |
Why?
|
| Trachea | 1 | 2011 | 293 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 3 | 2022 | 384 | 0.370 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2017 | 113 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2021 | 199 | 0.360 |
Why?
|
| Drug Monitoring | 2 | 2021 | 118 | 0.350 |
Why?
|
| Cohort Studies | 11 | 2022 | 2767 | 0.350 |
Why?
|
| Hypothermia, Induced | 2 | 2021 | 74 | 0.340 |
Why?
|
| Betacoronavirus | 3 | 2020 | 258 | 0.340 |
Why?
|
| Hospitalization | 10 | 2023 | 849 | 0.330 |
Why?
|
| Databases, Factual | 8 | 2020 | 814 | 0.330 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2021 | 67 | 0.330 |
Why?
|
| Prevalence | 11 | 2022 | 1239 | 0.330 |
Why?
|
| Young Adult | 15 | 2022 | 5976 | 0.330 |
Why?
|
| Phenotype | 8 | 2024 | 2378 | 0.330 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 170 | 0.330 |
Why?
|
| Algorithms | 5 | 2020 | 1830 | 0.330 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 484 | 0.320 |
Why?
|
| Resuscitation | 3 | 2017 | 100 | 0.320 |
Why?
|
| Risk Assessment | 12 | 2020 | 2261 | 0.320 |
Why?
|
| Global Health | 4 | 2017 | 193 | 0.320 |
Why?
|
| Electronic Health Records | 2 | 2023 | 319 | 0.320 |
Why?
|
| Chlorides | 2 | 2018 | 103 | 0.320 |
Why?
|
| Neoplasms | 2 | 2021 | 2898 | 0.310 |
Why?
|
| Interleukin-8 | 5 | 2022 | 86 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 930 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 44 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2018 | 263 | 0.300 |
Why?
|
| Matrix Metalloproteinase 8 | 5 | 2017 | 5 | 0.300 |
Why?
|
| Influenza, Human | 2 | 2023 | 329 | 0.290 |
Why?
|
| Pediatrics | 3 | 2016 | 344 | 0.290 |
Why?
|
| Health Resources | 2 | 2018 | 76 | 0.290 |
Why?
|
| Creatinine | 4 | 2023 | 338 | 0.290 |
Why?
|
| Glucocorticoids | 4 | 2023 | 352 | 0.280 |
Why?
|
| Age Factors | 6 | 2021 | 1851 | 0.280 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 18 | 0.280 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 190 | 0.260 |
Why?
|
| Disease Progression | 4 | 2023 | 1531 | 0.260 |
Why?
|
| Granzymes | 4 | 2017 | 93 | 0.250 |
Why?
|
| Pandemics | 5 | 2023 | 740 | 0.250 |
Why?
|
| Renal Replacement Therapy | 2 | 2022 | 30 | 0.250 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 183 | 0.250 |
Why?
|
| Caspases, Initiator | 1 | 2024 | 1 | 0.250 |
Why?
|
| Hypothermia | 2 | 2022 | 26 | 0.240 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2020 | 20 | 0.240 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 339 | 0.240 |
Why?
|
| Machine Learning | 2 | 2023 | 232 | 0.240 |
Why?
|
| Models, Statistical | 3 | 2020 | 574 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 23 | 0.230 |
Why?
|
| Time Factors | 7 | 2022 | 5210 | 0.230 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 11 | 0.230 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 39 | 0.230 |
Why?
|
| Meningitis, Aseptic | 1 | 2023 | 8 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1686 | 0.230 |
Why?
|
| Europe | 3 | 2018 | 309 | 0.220 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2023 | 16 | 0.220 |
Why?
|
| Case-Control Studies | 7 | 2023 | 1805 | 0.220 |
Why?
|
| Chemokine CCL3 | 3 | 2017 | 12 | 0.220 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 16 | 0.220 |
Why?
|
| Immunologic Factors | 2 | 2021 | 170 | 0.220 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 67 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 203 | 0.220 |
Why?
|
| Vomiting | 2 | 2016 | 193 | 0.210 |
Why?
|
| Muscle Proteins | 2 | 2000 | 132 | 0.210 |
Why?
|
| Blood Banks | 1 | 2022 | 7 | 0.210 |
Why?
|
| Osteonecrosis | 1 | 2022 | 21 | 0.210 |
Why?
|
| Interferon Type I | 1 | 2022 | 175 | 0.210 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 33 | 0.210 |
Why?
|
| Precision Medicine | 2 | 2016 | 395 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 379 | 0.200 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 27 | 0.200 |
Why?
|
| Delirium | 1 | 2022 | 66 | 0.200 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 15 | 0.200 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 73 | 0.200 |
Why?
|
| Odds Ratio | 5 | 2022 | 678 | 0.200 |
Why?
|
| Erythrocytes | 1 | 2022 | 255 | 0.190 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 21 | 0.190 |
Why?
|
| Mitochondria | 2 | 2014 | 535 | 0.190 |
Why?
|
| Vasoconstrictor Agents | 2 | 2020 | 53 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 154 | 0.190 |
Why?
|
| France | 1 | 2020 | 47 | 0.190 |
Why?
|
| Intubation | 1 | 2020 | 21 | 0.190 |
Why?
|
| Meningitis, Bacterial | 1 | 2020 | 13 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2000 | 4 | 0.190 |
Why?
|
| Fingers | 1 | 2020 | 68 | 0.180 |
Why?
|
| Oximetry | 1 | 2020 | 84 | 0.180 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 21 | 0.180 |
Why?
|
| Hypoxia | 2 | 2023 | 641 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 2 | 2000 | 503 | 0.180 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 39 | 0.180 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 470 | 0.180 |
Why?
|
| Hyperlactatemia | 1 | 2019 | 1 | 0.180 |
Why?
|
| Thiamine | 1 | 2019 | 8 | 0.180 |
Why?
|
| Hemorrhage | 1 | 2021 | 268 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2023 | 329 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2021 | 233 | 0.180 |
Why?
|
| Patient Discharge | 4 | 2023 | 300 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 255 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2019 | 37 | 0.170 |
Why?
|
| Treatment Outcome | 11 | 2021 | 7993 | 0.170 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1565 | 0.170 |
Why?
|
| Homeodomain Proteins | 2 | 2000 | 536 | 0.170 |
Why?
|
| Clinical Coding | 1 | 2019 | 23 | 0.170 |
Why?
|
| Lipids | 1 | 2020 | 269 | 0.170 |
Why?
|
| Down Syndrome | 2 | 2016 | 53 | 0.170 |
Why?
|
| Genetic Therapy | 2 | 2014 | 342 | 0.170 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 209 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2013 | 315 | 0.170 |
Why?
|
| Orexins | 1 | 2018 | 8 | 0.170 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 163 | 0.170 |
Why?
|
| Afibrinogenemia | 1 | 2018 | 1 | 0.160 |
Why?
|
| Syndrome | 2 | 2017 | 446 | 0.160 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2018 | 2 | 0.160 |
Why?
|
| Ethical Review | 1 | 2018 | 8 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2018 | 83 | 0.160 |
Why?
|
| Malnutrition | 1 | 2018 | 34 | 0.160 |
Why?
|
| Models, Theoretical | 3 | 2015 | 482 | 0.160 |
Why?
|
| Genetic Vectors | 4 | 2014 | 439 | 0.160 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 60 | 0.160 |
Why?
|
| Chest Wall Oscillation | 1 | 2017 | 5 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2019 | 2207 | 0.160 |
Why?
|
| Ethics Committees, Research | 1 | 2018 | 33 | 0.160 |
Why?
|
| Hemodynamics | 5 | 2021 | 710 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 318 | 0.160 |
Why?
|
| Body Mass Index | 2 | 2018 | 770 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 763 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 48 | 0.160 |
Why?
|
| Comorbidity | 2 | 2018 | 943 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 141 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2019 | 185 | 0.150 |
Why?
|
| Brain Injuries | 1 | 2020 | 161 | 0.150 |
Why?
|
| Aftercare | 3 | 2023 | 85 | 0.150 |
Why?
|
| Kidney | 2 | 2023 | 1241 | 0.150 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 293 | 0.150 |
Why?
|
| Clinical Alarms | 1 | 2017 | 16 | 0.150 |
Why?
|
| AIDS Vaccines | 2 | 2009 | 9 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 23 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 592 | 0.150 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2017 | 54 | 0.150 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 17 | 0.150 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 20 | 0.150 |
Why?
|
| Skin | 1 | 2020 | 554 | 0.150 |
Why?
|
| Textbooks as Topic | 1 | 2016 | 2 | 0.150 |
Why?
|
| Immunization, Secondary | 2 | 2009 | 30 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 182 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2021 | 695 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2018 | 256 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 115 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 47 | 0.150 |
Why?
|
| Animals | 15 | 2024 | 26582 | 0.140 |
Why?
|
| Adult | 11 | 2023 | 25648 | 0.140 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2016 | 9 | 0.140 |
Why?
|
| Heart | 1 | 2019 | 539 | 0.140 |
Why?
|
| Incidence | 4 | 2024 | 1577 | 0.140 |
Why?
|
| Chest Pain | 1 | 2016 | 42 | 0.140 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 37 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2016 | 49 | 0.140 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 120 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1036 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 69 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1197 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 160 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 177 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2016 | 97 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 41 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 1991 | 0.130 |
Why?
|
| Mice | 10 | 2024 | 11352 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 702 | 0.130 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2014 | 4 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 557 | 0.130 |
Why?
|
| Dependovirus | 1 | 2014 | 33 | 0.130 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2014 | 24 | 0.130 |
Why?
|
| ROC Curve | 4 | 2019 | 752 | 0.130 |
Why?
|
| Models, Biological | 2 | 2019 | 1749 | 0.130 |
Why?
|
| Survival Rate | 4 | 2021 | 1863 | 0.130 |
Why?
|
| Cross Infection | 1 | 2015 | 141 | 0.120 |
Why?
|
| Transcriptome | 2 | 2018 | 580 | 0.120 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2013 | 31 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 141 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 1139 | 0.120 |
Why?
|
| Proteolysis | 1 | 2014 | 100 | 0.120 |
Why?
|
| Stroke | 1 | 2023 | 965 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2015 | 297 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2022 | 1219 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2019 | 1538 | 0.110 |
Why?
|
| Macrophage Activation | 1 | 2013 | 46 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 257 | 0.110 |
Why?
|
| Antibodies, Bispecific | 1 | 2013 | 21 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2014 | 249 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 819 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2013 | 26 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 165 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 209 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1384 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1981 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2014 | 579 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2014 | 227 | 0.110 |
Why?
|
| Gagging | 1 | 2011 | 1 | 0.110 |
Why?
|
| Metapneumovirus | 1 | 2011 | 3 | 0.110 |
Why?
|
| Subcutaneous Emphysema | 1 | 2011 | 7 | 0.110 |
Why?
|
| Paramyxoviridae Infections | 1 | 2011 | 5 | 0.110 |
Why?
|
| Respiratory Aspiration | 1 | 2011 | 5 | 0.110 |
Why?
|
| Mediastinal Emphysema | 1 | 2011 | 6 | 0.100 |
Why?
|
| Clinical Protocols | 3 | 2017 | 156 | 0.100 |
Why?
|
| Philadelphia | 3 | 2017 | 16 | 0.100 |
Why?
|
| Positive-Pressure Respiration | 1 | 2011 | 41 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 2232 | 0.100 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2018 | 190 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2705 | 0.100 |
Why?
|
| Immunomodulation | 2 | 2021 | 55 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2011 | 147 | 0.100 |
Why?
|
| Equipment Design | 1 | 2011 | 406 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2023 | 428 | 0.090 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 104 | 0.090 |
Why?
|
| Bronchoscopy | 1 | 2011 | 152 | 0.090 |
Why?
|
| Acute Disease | 3 | 2018 | 826 | 0.090 |
Why?
|
| Adenoviruses, Simian | 1 | 2009 | 2 | 0.090 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 2 | 0.090 |
Why?
|
| Rats | 3 | 2022 | 3990 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3362 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 813 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 456 | 0.090 |
Why?
|
| Neurons | 1 | 2018 | 1546 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1920 | 0.090 |
Why?
|
| Seizures | 1 | 2011 | 297 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2022 | 839 | 0.080 |
Why?
|
| Oxygen | 1 | 2013 | 726 | 0.080 |
Why?
|
| Adenoviruses, Human | 2 | 2009 | 41 | 0.080 |
Why?
|
| Morbidity | 2 | 2020 | 148 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 894 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 879 | 0.080 |
Why?
|
| Decision Trees | 2 | 2019 | 63 | 0.080 |
Why?
|
| Neutralization Tests | 2 | 2022 | 77 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2019 | 334 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1621 | 0.070 |
Why?
|
| Fluid Therapy | 2 | 2017 | 50 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2426 | 0.070 |
Why?
|
| Inflammation | 2 | 2024 | 920 | 0.070 |
Why?
|
| Factor IX | 1 | 2006 | 4 | 0.070 |
Why?
|
| Obesity | 2 | 2023 | 963 | 0.070 |
Why?
|
| Genotype | 2 | 2023 | 1851 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 1047 | 0.070 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 371 | 0.070 |
Why?
|
| Hepatocytes | 1 | 2006 | 127 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2020 | 327 | 0.060 |
Why?
|
| Cause of Death | 2 | 2017 | 277 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2903 | 0.060 |
Why?
|
| Adenovirus E1 Proteins | 1 | 2003 | 1 | 0.060 |
Why?
|
| HIV Antigens | 1 | 2003 | 4 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2003 | 12 | 0.060 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2023 | 14 | 0.060 |
Why?
|
| Endoglin | 1 | 2023 | 20 | 0.060 |
Why?
|
| Angiopoietin-1 | 1 | 2023 | 4 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1673 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2000 | 1208 | 0.060 |
Why?
|
| PAX7 Transcription Factor | 2 | 2000 | 4 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 379 | 0.060 |
Why?
|
| Crowding | 1 | 2023 | 6 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3092 | 0.060 |
Why?
|
| Microglia | 1 | 2024 | 102 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 42 | 0.060 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2022 | 5 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 50 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2023 | 48 | 0.060 |
Why?
|
| Renin | 1 | 2023 | 79 | 0.060 |
Why?
|
| Masks | 1 | 2023 | 29 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2023 | 135 | 0.060 |
Why?
|
| Thrombomodulin | 1 | 2022 | 7 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 999 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2022 | 71 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 92 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2022 | 143 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2022 | 62 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 40 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 65 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 44 | 0.050 |
Why?
|
| Cannula | 1 | 2022 | 47 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 223 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 13 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2501 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2000 | 1565 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2022 | 60 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 196 | 0.050 |
Why?
|
| Italy | 1 | 2021 | 106 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 267 | 0.050 |
Why?
|
| Antifibrinolytic Agents | 1 | 2021 | 30 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 1 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 137 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 21 | 0.050 |
Why?
|
| Canada | 1 | 2021 | 204 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 32 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 187 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 105 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 122 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 204 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 136 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 728 | 0.050 |
Why?
|
| HIV Infections | 1 | 2009 | 772 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 103 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2021 | 113 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
| Piperacillin | 1 | 2020 | 7 | 0.050 |
Why?
|
| Temperature | 1 | 2022 | 396 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 11 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 27 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 567 | 0.050 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 23 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3640 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2020 | 40 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 80 | 0.050 |
Why?
|
| Streptococcus agalactiae | 1 | 2020 | 11 | 0.050 |
Why?
|
| APACHE | 1 | 2020 | 21 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 154 | 0.050 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2000 | 23 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 32 | 0.050 |
Why?
|
| Age of Onset | 1 | 2021 | 310 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2000 | 51 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 1540 | 0.050 |
Why?
|
| Punctures | 1 | 2019 | 29 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2003 | 559 | 0.050 |
Why?
|
| Ligation | 1 | 2019 | 51 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 112 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 428 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2020 | 216 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2020 | 57 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 220 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2000 | 100 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 1999 | 40 | 0.040 |
Why?
|
| Fungi | 1 | 2020 | 65 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 369 | 0.040 |
Why?
|
| Cecum | 1 | 2019 | 68 | 0.040 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 47 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 297 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 1999 | 42 | 0.040 |
Why?
|
| Lipocalin-2 | 1 | 2019 | 38 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 376 | 0.040 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 64 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 162 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 596 | 0.040 |
Why?
|
| Viruses | 1 | 2020 | 78 | 0.040 |
Why?
|
| Cystatin C | 1 | 2019 | 31 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 444 | 0.040 |
Why?
|
| Osteopontin | 1 | 2019 | 47 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 90 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2024 | 628 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 429 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 103 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 592 | 0.040 |
Why?
|
| South America | 1 | 2018 | 29 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2000 | 265 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2000 | 166 | 0.040 |
Why?
|
| Neurosurgery | 1 | 2020 | 84 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 421 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 95 | 0.040 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2018 | 1 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 185 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 272 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 456 | 0.040 |
Why?
|
| Ghrelin | 1 | 2018 | 29 | 0.040 |
Why?
|
| Hyperphagia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Coma | 1 | 2018 | 44 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 105 | 0.040 |
Why?
|
| North America | 1 | 2018 | 180 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 307 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 105 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2020 | 290 | 0.040 |
Why?
|
| Ohio | 1 | 2017 | 37 | 0.040 |
Why?
|
| Calcitonin | 1 | 2017 | 38 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2017 | 25 | 0.040 |
Why?
|
| International Cooperation | 1 | 2017 | 127 | 0.040 |
Why?
|
| Acidosis | 1 | 2017 | 55 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 124 | 0.040 |
Why?
|
| Vital Signs | 1 | 2017 | 38 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 56 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1513 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2017 | 88 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2016 | 34 | 0.040 |
Why?
|
| Platelet Count | 1 | 2016 | 92 | 0.040 |
Why?
|
| Disabled Children | 1 | 2016 | 43 | 0.040 |
Why?
|
| Bacteria | 1 | 2020 | 447 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 33 | 0.040 |
Why?
|
| Spleen | 1 | 2017 | 430 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2015 | 4 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2016 | 47 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 476 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1999 | 374 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2015 | 5 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 268 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 98 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 459 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 164 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 123 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 2015 | 21 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 84 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 638 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2015 | 45 | 0.030 |
Why?
|
| Injections, Epidural | 1 | 2014 | 6 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 273 | 0.030 |
Why?
|
| Pan troglodytes | 2 | 2009 | 197 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 327 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 108 | 0.030 |
Why?
|
| Fever | 1 | 2015 | 125 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 145 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Pneumothorax | 1 | 2015 | 52 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 996 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 240 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 373 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1313 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 153 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 180 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 170 | 0.030 |
Why?
|
| Sleep | 1 | 2018 | 444 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 674 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2014 | 393 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 165 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 159 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 335 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 429 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2013 | 20 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 602 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2014 | 47 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 98 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Motor Neurons | 1 | 2014 | 162 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 236 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2014 | 510 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 428 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 149 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 239 | 0.030 |
Why?
|
| Sirolimus | 1 | 2014 | 169 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 916 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 751 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 692 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 860 | 0.030 |
Why?
|
| Brain | 1 | 2022 | 2216 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 296 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2357 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 615 | 0.030 |
Why?
|
| Burns | 1 | 2013 | 131 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 969 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2015 | 376 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 346 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 584 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1284 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1924 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2009 | 17 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 66 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 177 | 0.020 |
Why?
|
| HIV-1 | 1 | 2009 | 163 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2009 | 459 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 425 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 307 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 168 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2006 | 213 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 152 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 345 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 3241 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2003 | 21 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2003 | 16 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 62 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2003 | 19 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2006 | 337 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 89 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2006 | 295 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 498 | 0.010 |
Why?
|
| PAX3 Transcription Factor | 1 | 1999 | 11 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 1999 | 50 | 0.010 |
Why?
|
| Plasmids | 1 | 1999 | 287 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2468 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 18415 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 416 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1999 | 201 | 0.010 |
Why?
|
| Exons | 1 | 1999 | 450 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1041 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 25028 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 2062 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 2330 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1135 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 3030 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 926 | 0.010 |
Why?
|